Drug General Information (ID: DDIW7AFY16)
Drug Name			Ibritumomab tiuxetan		Drug Info		Niraparib		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Poly (Adp-Ribose) Polymerase Inhibitors

Mechanism of Ibritumomab tiuxetan-Niraparib Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Ibritumomab tiuxetan				Niraparib
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Ibritumomab tiuxetan and Niraparib

Recommended Action
Management		Caution is advised if niraparib is prescribed with other myelosuppressive agents.

References
1	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.